SynthesisCancer medicine2019
Prognostic and diagnostic significance of circRNAs expression in hepatocellular carcinoma patients: A meta-analysis.
Synthesis in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Circular RNA MYLK as a prognostic biomarker in patients with cancers: A systematic review and meta-analysis.Cancer reports (Hoboken, N.J.) · 2022Pooled it
- Prognostic and Clinicopathological Significance of Circular RNA circ-ITCH Expression in Cancer Patients: A Meta-analysis.BioMed research international · 2021Pooled it
- Diagnostic Accuracy of Serum/Plasma Circular RNAs and the Combination of Circular RNAs and α-Fetoprotein for Detecting Hepatocellular Carcinoma: A Meta-Analysis.Frontiers in genetics · 2021Pooled it
- A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectal cancer.BMC cancer · 2019Pooled it
- Prognostic and diagnostic significance of circRNAs expression in hepatocellular carcinoma patients: A meta-analysis.Cancer medicine · 2019Pooled it
- Systematic Review and Meta-Analysis of the Utility of Circular RNAs as Biomarkers of Hepatocellular Carcinoma.Canadian journal of gastroenterology & hepatology · 2019Pooled it
- Investigation of Circular RNA Expression Profiles in Ultrasound-guided Incomplete Radiofrequency Ablation Transplanted Tumor Models of Human Liver Cancer.Molecular biotechnology · 2025Article
- Novel Biomarkers for Early Detection of Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2024Review
- Biological and clinical implications of hsa_circ_0086720 in gastric cancer and its clinical application.Journal of clinical laboratory analysis · 2022Article
- Emerging roles of circular RNAs in liver cancer.JHEP reports : innovation in hepatology · 2022Review
- HCC biomarkers - state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice.Frontiers in oncology · 2022Review
- Recent Update on the Role of Circular RNAs in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2021Review
- Circ_0000517 Contributes to Hepatocellular Carcinoma Progression by Upregulating TXNDC5 via Sponging miR-1296-5p.Cancer management and research · 2020Article
- Circular RNA Expression Profiles and the Pro-tumorigenic Function of CircRNA_10156 in Hepatitis B Virus-Related Liver Cancer.International journal of medical sciences · 2020Article
- Dysregulated Expression of Circular RNAs Serve as Prognostic and Clinicopathological Markers in Cancer.Journal of Cancer · 2019Article
- Accuracy Evaluation of Circular RNA in Diagnosing Lung Cancer in a Chinese Population.Disease markers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) as novel biomarkers are widely investigated in various cancers. The aim of our study was to reveal the clinicopathological, prognostic, and diagnostic features of circRNAs in human hepatocellular carcinoma (HCC). A systematical search was conducted on PubMed, Scopus, Web of Science (WOS), EMBASE, and the Cochrane Library databases. Eligible studies reporting on the association among circRNAs and clinicopathological, prognostic, diagnostic values of HCC patients were included. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were utilized to assess clinicopathological parameters, sensitivity, and specificity, and hazard ratios (HRs) were to evaluate overall survival (OS). 17 eligible studies which included 7 for clinicopathological features, 10 for prognosis, and 8 for diagnosis were in our study. As for clinicopathological parameters, high expression of oncogenic circRNAs had a significant association with poor clinicopathological features and tumor-suppressor circRNAs proved the contrary. In terms of the prognostic values, oncogenic circRNAs had a negative influence on overall survival (OS: HR = 3.39, 95%Cl: 2.59-4.19), and high expression of tumor-suppressor circRNAs was relevant to improved survival outcomes (OS: HR = 0.46, 95%Cl: 0.37-0.56). The pooled diagnostic outcomes indicated an area under the curve (AUC) of 0.84, with sensitivity of 82% and specificity of 72% in discriminating HCC from controls. Our study indicates that circRNAs may be important biomarkers for prognostic and diagnostic values of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.